Creatine reduced brain injury signs in adolescent rats

Key Takeaways

• In adolescent male rats with severe traumatic brain injury, two weeks of post-injury creatine was linked to smaller cortical lesions and better maze performance.
• The study reported about a 60% reduction in cortical lesion volume and about a 50% lower escape latency in the Barnes maze versus injured untreated rats.
• Researchers also found less blood-brain barrier disruption, less epileptiform activity and better markers of mitochondrial function.
• The proposed mechanism involves preserved Na+,K+-ATPase activity through better mitochondrial integrity, but that pathway remains correlational in this study.
• This was a male-only rat experiment at a single time point, so it should not be read as proof that creatine improves outcomes after human traumatic brain injury.
• For everyday supplement users, the study mainly strengthens the broader case that creatine supports cellular energy systems, not that people should self-treat brain injury with it.

What the rat study found

The news here is straightforward: in adolescent male rats exposed to severe traumatic brain injury, creatine given after the injury was associated with better early outcomes across several brain-health measures. According to the abstract, two weeks of oral creatine at 300 mg/kg reduced blood-brain barrier disruption, cut cortical lesion volume by roughly 60%, improved spatial-memory performance in the Barnes maze by about 50% and reduced epileptiform activity.

Those are notable signals because traumatic brain injury is not just the initial mechanical insult. A large part of the damage can come from so-called secondary injury processes that unfold afterward, including mitochondrial dysfunction, oxidative stress, disrupted ion balance and abnormal neuronal excitability. This paper places creatine in that post-injury window, which is more clinically interesting than a purely pre-injury model.

The authors also report that the injury protocol lowered creatine levels in the hippocampus and produced broad signs of mitochondrial impairment. These included worsened mitochondrial membrane potential, lower activity of several energy-related enzymes and more oxidative stress. In parallel, Na+,K+-ATPase activity was inhibited, which matters because that membrane pump helps maintain the ion gradients neurons need to function normally.

In short, the study suggests creatine helped preserve brain-energy machinery in this model, and that preservation tracked with less hyperexcitability and better cognitive performance. That is promising basic science. It is not yet a green light to assume the same effects occur in people with concussion or severe traumatic brain injury.

How the experiment was designed

This was a controlled animal experiment, not a human clinical trial. The researchers used 35-day-old male rats subjected to severe fluid percussion injury, a standard preclinical model of traumatic brain injury. After injury, the animals received oral creatine supplementation at 300 mg/kg for two weeks.

The abstract indicates the team then evaluated several categories of outcome:

• Structural injury: blood-brain barrier disruption and cortical lesion volume
• Behaviour: spatial memory in the Barnes maze
• Brain activity: hippocampal theta/delta rhythm changes and epileptiform activity
• Cellular energetics: mitochondrial membrane potential, enzyme activity and oxidative stress markers
• Ion regulation: Na+,K+-ATPase activity

That breadth is a strength. It lets the authors connect behaviour and electrophysiology to plausible cellular mechanisms rather than reporting one isolated endpoint. The paper also focused on post-injury supplementation, which is more relevant to real-world care than studies that only test preventive dosing before trauma occurs.

Still, readers should keep the model in perspective. These were adolescent rats, not adults, and only males were included. The outcomes were assessed at a single early time point, so the study does not tell us whether benefits persist long term. And because the mechanistic chain is inferred from associated changes rather than directly proven step by step, the proposed mitochondrial-to-Na+,K+-ATPase pathway should be viewed as biologically plausible, not established fact.

Why the mitochondrial mechanism matters

Creatine is best known in sport for helping replenish phosphocreatine and support rapid ATP turnover during high-intensity effort. But the same energy-buffering role is one reason scientists have long been interested in creatine beyond muscle, especially in tissues with high and fluctuating energy demand such as the brain.

In this study, the authors argue that severe brain injury triggered a cascade: mitochondrial dysfunction and oxidative stress impaired Na+,K+-ATPase activity, which then contributed to neuronal hyperexcitability and cognitive deficits. Creatine appeared to interrupt that cascade by preserving mitochondrial integrity.

That framing matters because it links the supplement to a coherent biological story rather than a vague claim that it is simply “neuroprotective”. Na+,K+-ATPase is one of the cell's major ATP consumers. When energy supply falters, ion gradients can destabilise, neurons become more excitable and network function can deteriorate. If creatine helps support ATP buffering during that vulnerable period, the downstream effects observed in this rat model make physiological sense.

Even so, mechanism-heavy animal papers can tempt people to overgeneralise. What this study really shows is that, in one severe-injury model, creatine tracked with better mitochondrial and electrophysiological outcomes. It does not prove creatine will prevent post-traumatic seizures, preserve cognition or reduce lesion burden in human patients. Translational gaps remain large, especially across species, ages and injury severity.

For readers wanting a broader overview of established creatine science, our creatine guides cover where the evidence is strongest and where it is still emerging.

What it means in practice for creatine users

For most readers, the practical takeaway is modest: this paper adds to the rationale for creatine as a cellular-energy supplement, but it does not justify self-treating traumatic brain injury. If you or someone else has a concussion or more severe head injury, standard medical assessment and follow-up come first.

For otherwise healthy people who already use creatine for training, the broader evidence base still points to creatine monohydrate as the default form. Typical evidence-based use is either:

• Loading: about 20 g/day split into 4 doses for 5-7 days
• Maintenance: about 3-5 g/day thereafter

Those mainstream protocols come from the much larger sports-nutrition literature, not from this brain-injury rat paper. If you want help estimating a practical daily intake, our creatine dosage calculator can help, and our best creatine rankings and creatine brand reviews are useful if you are comparing monohydrate products.

One nuance worth noting: the rat dose in this study should not be copied directly by humans. Animal dosing does not translate in a simple milligram-per-kilogram way, and the setting here was severe experimental brain trauma under controlled conditions.

So what should a regular gym-goer do with this news? Mostly, view it as interesting support for creatine's role in energy metabolism and brain research, while keeping expectations grounded. The strongest human evidence for creatine still concerns exercise performance, lean mass support and high-intensity training adaptation rather than treatment of neurological injury.

How this fits the wider creatine evidence

This study does not stand alone, but it sits in a part of the literature that is still developing. Creatine has long been among the most studied sports supplements, with strong evidence for safety and efficacy in appropriate contexts, especially as creatine monohydrate. The International Society of Sports Nutrition position stand remains one of the clearest summaries of that evidence base: Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine.

There is also a growing discussion around brain and cognitive applications, but the human evidence there is more mixed and context-dependent than in sport. Reviews and explainers such as Antonio et al. (2021), Common questions and misconceptions about creatine supplementation help clarify what creatine is known to do, what remains uncertain and why monohydrate stays the benchmark.

Where does this new rat paper fit? It strengthens preclinical evidence that creatine may help protect energy metabolism in stressed neural tissue. That is scientifically meaningful because traumatic brain injury involves exactly the kinds of bioenergetic disruptions creatine could plausibly influence.

But the ranking of evidence still matters. A mechanistic animal study is useful for hypothesis generation and biological plausibility. It is not the same as a randomised controlled trial in people with traumatic brain injury. Until human trials confirm clinically relevant benefits, this finding should be treated as promising but preliminary.

If you are mainly shopping for a straightforward monohydrate product rather than following the research, our creatine product catalog organises common options in one place.

Bottom line

This new paper reports that post-injury creatine supplementation improved several early outcomes in adolescent male rats after severe traumatic brain injury, including smaller lesions, less epileptiform activity and better spatial-memory performance. The authors also present a plausible mechanism centred on preserved mitochondrial function and maintained Na+,K+-ATPase activity.

That is important and interesting research. It suggests creatine may have relevance beyond muscle by helping buffer energy failure in injured brain tissue. But the finding is still preclinical. It does not show that creatine can treat concussion, prevent seizures or improve recovery after traumatic brain injury in humans.

For people already taking creatine, this study is best read as another reason the molecule continues to attract serious research attention. For people considering creatine, the practical message remains conventional: if you use it, choose monohydrate, use evidence-based dosing and buy from a reputable product line.

For clinicians and researchers, the next step is obvious: test whether similar post-injury effects appear in well-designed human studies, in both sexes, across different ages and over longer follow-up periods. Until then, this is a promising animal study with real mechanistic value, not a proven therapy.

Creatine and severe brain injury: what this study showed

• ~60% Lower cortical lesion volume — Reported in creatine-treated injured rats versus injured untreated rats.
• ~50% Lower Barnes maze escape latency — Suggests less spatial-memory impairment in the treated group.
• 300 mg/kg Post-injury rat dose — Oral creatine given for two weeks; not a direct human dosing guide.
• 3-5 g/day Typical human maintenance dose — Mainstream creatine monohydrate maintenance from broader sports-nutrition evidence.

Frequently Asked Questions

Sources & Further Reading

• Kreider et al. (2017), ISSN Position Stand: Safety and Efficacy of Creatine — JISSN
• Antonio et al. (2021), Common questions and misconceptions about creatine supplementation — JISSN